Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;9(3):1518-1525.
doi: 10.21037/tau.2019.09.12.

Targeting the cancer lesion, not the whole prostate

Affiliations
Review

Targeting the cancer lesion, not the whole prostate

Nishant Bedi et al. Transl Androl Urol. 2020 Jun.

Abstract

Modern cancer treatment aims to conserve as much healthy tissue as possible. This has been challenging in the treatment of prostate cancer due to the difficulty in imaging the gland and concerns over leaving multifocal cancer untreated. With improvements in imaging and understanding of multifocal prostate cancer evidence now shows accurate treatment of just the primary focus of cancer or the index lesion can control progression or recurrence of the disease. Many different energy sources are now available to target the cancer lesion within the prostate with less significant side-effects on urinary and sexual function compared to radical treatment. Evidence shows that men value these functions highly and would even trade years of life in exchange for preserved retention of continence or erectile function. Focal treatment of prostate cancer aims to provide both cancer control and preservation of sexual and urinary functions so that men do not have to make a choice between the two. This is a treatment option that men clearly want and deserve.

Keywords: Prostate cancer; cryotherapy; focal brachytherapy; focal radiofrequency ablation (focal RFA); focal therapy; high-intensity focused ultrasound (HIFU); index lesion; irreversible electroporation (IRE); laser interstitial therapy (LITT); photodynamic therapy (PDT); vascular-targeted photodynamic therapy (VTP).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2019.09.12). The series “Prostate Imaging and Focal Therapy” was commissioned by the editorial office without any funding or sponsorship. HUA served as an unpaid Guest Editor of the series. DR is a clinical research fellow funded by a research grant from Prostate Cancer UK. HUA reports grants and personal fees from Sonacare, grants and personal fees from Boston Scientific, grants and personal fees from Sophiris Biocorp, grants from Trod medical, NB has no other conflicts of interest to declare.

Similar articles

Cited by

References

    1. Humphrey PA. Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Pathol 1993;17:468-72. 10.1097/00000478-199305000-00005 - DOI - PubMed
    1. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65. 10.1038/nm.1944 - DOI - PMC - PubMed
    1. Karavitakis M, Ahmed HU, Abel PD, et al. Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy. Ther Adv Urol 2012;4:155-60. 10.1177/1756287212447092 - DOI - PMC - PubMed
    1. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-7. 10.1038/nature14347 - DOI - PMC - PubMed
    1. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 2013;20:204-9. 10.1097/MED.0b013e328360332a - DOI - PubMed